GENE ONLINE|News &
Opinion
Blog

2022-07-08|

How Governments Around the World Should Respond to the Mounting Costs of Gene and Cell Therapy?

by GeneOnline
Share To
With the advancement of science, gene and cell therapies have revolutionized the treatment of cancer and rare diseases. However, are governments adequately prepared to respond to the mounting cost of drugs, or can payers and pharmaceutical companies work out an agreement for reasonable price?
As major pharmaceutical companies are investing more in new and novel medical technologies, the concept of precision medicine is becoming increasingly popular. At the same time, gene and cell therapies are becoming ever more costly due to their complex and capital-intensive manufacturing processes and consequent difficulties in reducing costs.
Take Gilead's Hepatitis C drug Sovaldi and its successor Harvani for example, their prices forced the FDA to hold congressional hearings, reviews and discussions on whether the US health insurance can continue to afford such high prices for drugs. With the development of gene and cell therapy, it is likely that the same scrutiny will be imposed again if the prices stay high. Therefore, it is hoped that the major pharmaceutical companies will consider the feasibility of affordability for the public or the government when setting prices of new gene and cell therapies in order to avoid the same issue, otherwise they may face a difficult barrier to break through when promoting their drugs in the future.

GO Prime with only $1.49 now

LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!